Literature DB >> 34979686

COVID-19 in Patients with Myasthenia Gravis: Mechanisms of Respiratory Failure.

Jagarlapudi M K Murthy1, Abhinay K Gutta1, Muralidhar Reddy Yerasu1, Santhosh Kumar Boorgu1, Syed Osman1, Shyam K Jaiswal1, Lalitha Pidaparthi1, Bhavani P Gudavalli2.   

Abstract

This report describes a patient with thymomatous myasthenia gravis (MG) with aplastic anemia in pharmacological remission and COVID-19 who developed respiratory failure in the course of the disease and reviews the published literature on this topic. Analysis of the clinical characteristics of the eight patients with MG including our patient suggests two possible mechanisms for respiratory failure: myasthenic crisis (MC) or pulmonary complications of COVID-19. Patients with MC were young women in high-grade MGFA Class whereas patients with respiratory failure due to pulmonary complications of COVID-19 were elderly men in pharmacological remission or MGFA Class I. These observations suggest that COVID-19, like other infections, may precipitate MC in patients with severe grade MG before COVID-19. The only differentiating feature between the two types of failure was severity myasthenic weakness. This clinical distinction has management implications. These observations need to be validated in a larger sample.

Entities:  

Keywords:  COVID-19; Myasthenia gravis; myasthenic crisis; pulmonary complications; respiratory failure

Mesh:

Year:  2021        PMID: 34979686     DOI: 10.4103/0028-3886.333460

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  3 in total

1.  The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis.

Authors:  Giuliana Galassi
Journal:  Neurol Sci       Date:  2022-06-27       Impact factor: 3.830

2.  Letter response to "The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis".

Authors:  Paulo Ribeiro Nóbrega; Pedro Helder de Oliveira Junior; Hermany Capistrano de Freitas; José Artur Costa D'almeida; Cleonísio Leite Rodrigues
Journal:  Neurol Sci       Date:  2022-08-08       Impact factor: 3.830

3.  Reply to Letter response to "The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis".

Authors:  Giuliana Galassi; Alessandro Marchioni
Journal:  Neurol Sci       Date:  2022-09-07       Impact factor: 3.830

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.